Ajanta Pharma Limited has announced that its Board of Directors will convene on November 3, 2025, to deliberate on several key financial matters, including the declaration of the company's first interim dividend for the fiscal year ending March 31, 2026.

Key Points of the Announcement

• Board Meeting Date: November 3, 2025
• Agenda Items:
  • Consider declaring the first interim dividend for FY 2025-26
  • Review unaudited financial results for Q2 and H1 FY 2025-26
  • Potentially fix the record date for dividend payment

Dividend Considerations

The pharmaceutical company has informed the stock exchanges that if an interim dividend is declared, the Board will consider setting November 10, 2025, as the record date for determining shareholder eligibility.

Financial Review

In addition to the dividend deliberation, the Board meeting will focus on reviewing the company's financial performance. The agenda includes:

• Examination of unaudited financial results for the second quarter (Q2) of FY 2025-26
• Review of half-yearly (H1) financial results ending September 30, 2025

Regulatory Compliance

Ajanta Pharma's announcement aligns with regulatory requirements, as stated in their official communication:

"Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared."

Investor Implications

Shareholders and potential investors should mark these dates:

Investors are advised to monitor the outcome of this board meeting, as it may impact the company's stock price and provide insights into Ajanta Pharma's financial health and shareholder return policies.

The company has requested the stock exchanges to disseminate this information to all concerned parties, ensuring transparency and compliance with market regulations.

Ajanta Pharma Limited , a prominent player in the pharmaceutical sector, has witnessed continued share pledging activities by its promoters. The latest disclosures show significant new pledge creations by key promoter Aayush Agrawal, adding to the series of recent transactions by promoters.

Latest Pledge Creation by Aayush Agrawal Trust

In the most recent disclosure dated December 31, 2025, Aayush Agrawal Trust reported the creation of a pledge on equity shares under SEBI SAST Regulations 2011. The transaction details are:

This follows another substantial pledge creation earlier in December, demonstrating ongoing financing activities by the promoter group.

Previous December 2025 Transactions

Prior to the latest disclosure, Aayush Agrawal had reported a major pledge creation on December 26, 2025, involving 16,02,500 shares for bank guarantee and increased loan purposes. Earlier in December 2025, Aayush Agrawal had also reported simultaneous pledge creation and release activities on December 17, 2025, involving pledging 6,38,500 shares while releasing 4,50,000 shares with Bajaj Finance Ltd.

Earlier Aayush Agrawal Activities

In October 2025, Aayush Agrawal had pledged 6,45,000 shares for new loan and additional margin purposes, disclosed on October 1, 2025, with multiple financial institutions including Deutsche Investments India Pvt Ltd, HSBC InvestDirect Financial Services India Ltd, and Jio Finance Ltd.

Ravi Agrawal's Share Transactions

In a separate disclosure dated October 3, 2025, Ravi Agrawal, another promoter of Ajanta Pharma, reported both creation and release of pledges:

Significant transactions included pledge creation of 10,50,000 shares with Emerging India Credit Opportunities Fund for business financing, along with multiple smaller transactions with various financial institutions.

Promoter Pledging Activity Summary

The recent series of pledging activities by Ajanta Pharma promoters demonstrates active financial management strategies. With multiple pledge creations by Aayush Agrawal Trust, including the latest 1,27,660 shares and earlier 16,02,500 shares in December 2025, the promoters continue to utilize their shareholdings for various financing requirements. These transactions are part of routine corporate financing activities and reflect ongoing business requirements including bank guarantees and loan facilities.